Contents

Volume 81 Issue 9 | ARD September 2022

Viewpoint

1203 Developing guidelines for ultrarare rheumatic disorders: a bumpy ride
D Picken, M Romano, D Aleutia, B M Feldman, R Goldbach-Mansky, L Carmona, E Demirkaya

Rheumatoid arthritis

1206 Inflammatory correlates of the Patient Global Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis
S Bogatu, I. De Stefano, B D’Onofrio, A Nicosoni, E Marini, M di Lenia, G Sakellaris, E G Favalli, A Manzo, R Caporali, C Montecucco

1213 Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming

1214 Distinct striotomal and immune cell interactions shape the pathogenesis of rheumatoid and psoriotic arthritis
A Flexous, C M Smith, O Tyman, N Nazo, V Kostova, S M Wade, M Hanbin, C Cunningham, V Marzalek, M Canavan, J M Fletcher, R H Mullain, S Cole, L Y Hoo, M G Menagef, S Nagdev, J D Veale, U Fedor

Spondyloarthritis

1243 MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group
X Boruteli, M Ostergaard, R GW Lambin, L Thisted, P M Mackaide, S J Pedersen, U Weber, M de Hooge, J Sieper, D Poddaum, R Mudawad, D van der Heide, R BM Lunderv, WP Malysmycwich

1252 Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis
M Tougas, V Rios Rodriguez, A Dilliboyl, F Poff, A Propstegpe, M Verba, J Radembr, H Hiesel, J Sieper, M Mudawad, D Poddaum

Systemic lupus erythematosus

1260 Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades
A Diante-García, M Hoczug, M Valenzuela-Almada, S A Osu-Ononmole, J T Dutih, A Sanchez-Rodriguez, S Q Dong, R E Glasser, H E Longenfeld, G S Alcaín, C G Helms, C S Cawson

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus

1273 Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study

Systemic sclerosis

1281 Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching

Vasculitis

1290 Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids

More Contents ▶

Disclaimer: The Editor of ARD has been granted editorial freedom and ARD is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. ARD is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by ARD does not imply endorsement. Neither BMJ nor BMA Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from ARD (except for liability which cannot be legally excluded).

Copyright: © 2022 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved. No part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd supported by the BMJ Journals open access scheme.

This article has been chosen by the Editor to be of special interest and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See http://authors.bmj.com/open-access/

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.
### Contents

**Autoimmunity**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1301</td>
<td>Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component</td>
</tr>
</tbody>
</table>


### Osteoporosis

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1313</td>
<td>Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatoid arthritis</td>
</tr>
</tbody>
</table>

E Weie, D Hocher, D Schlauburg, A Palomaki, S Hermann, T Buttgereit, R Biesen, C-R Bumser, Y Palomaki, M Boers, J H Stone, C Dejaco, F Buttgereit |

### Crystal arthropathies

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1323</td>
<td>Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis</td>
</tr>
</tbody>
</table>

S K Tedeschi, W Huang, K Yoshida, D H Solomon |

### Images in rheumatology

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1330</td>
<td>Clinical image: bone erosions in a young man</td>
</tr>
</tbody>
</table>

L Bastard, B Hagege, M Breban, H Gouze |

### Letters

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1331</td>
<td>Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic</td>
</tr>
</tbody>
</table>

L De Stefano, B D’Onofrio, G Sakellariou, A Manzo, C Montecucco, S Bugatti |

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1332</td>
<td>Cross-reactivity of anti-modified protein antibodies is also present in predisease and individuals without rheumatoid arthritis</td>
</tr>
</tbody>
</table>

S Rejn, A S Breher, S Ranapat-Dalakpist, A Kawakami, T Matuda, S Kawashimi, M Tama, D Van der Woude, R E M Toes |

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1334</td>
<td>Sequential interleukin-17/Interleukin-23 inhibition in treatment-refractory psoriatic arthritis</td>
</tr>
</tbody>
</table>

D Simon, F Faqui, G Schett |

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1336</td>
<td>Determination of the minimal clinically important difference (MCID) of the physician global assessment (PGA) in SLE</td>
</tr>
</tbody>
</table>

E W Anderson, M Mackay, G Franchin, C Anawo |

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1337</td>
<td>SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection</td>
</tr>
</tbody>
</table>

E Morales, M Gallino |

### 1338 | Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine |

J Dued, P I Bourgo, N Le Core, C Ruiz Tagle, C Martnez-Valdéhenato, M Castro, V Metzdorf, P Niemann, M Ebna Belds |

### Electronic pages

**e157** | More evidence on which biologic and which pathway is key in severe-critical COVID-19 pneumonia |

G Ferraccioli |

**e158** | Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli |

E Della-Torre, C Ciempichio, G Cavalli, G De Luca, F Ciceri, A Zangrillo, I Dagna |

**e159** | Correspondence on: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ |


**e160** | Response to: ‘Correspondence on Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Poutely et al |

N Deldicque, M Poutely, J Lohmer, C Bentezol, C Beyler, A Deho, U Monceur, A Faye, I Mallo, Great Paris Region (CP8) Kawa-COVID-19 consortium |

**e161** | Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis |

M E Singer, D C Kaelber, M J Antonelli |

**e162** | Response to: ‘Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis’ by Singer et al |

M F Ugarte-Gil, M F König, P Korsten, F Berentbaum, A H Kim, J A Sparks |

**e163** | Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist’ by Graef et al |

C H Lo, Y-H Wang, C F Tsai, K C Chan, I C Li, T H Lo, C H Su, J C-C Wei |

**e164** | Response to: ‘Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist’ by Graef et al’ by Lo et al |

A Duarte-Cárzana, E R Graef, J W Liew, M F König, A H Kim, J A Sparks |

**e165** | Correspondence on ‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer et al |

R Gai, Q Wang, H Zhng, S Wu, X-J Wzn, S-M Dai
Response to: “2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus” by Aringer et al by Cui et al

Women’s journey in Mexican rheumatology. Comment on ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga et al by Colunga-Pedraza et al

Response to: ‘Women’s journey in Mexican rheumatology. Comment on ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga et al’ by Colunga-Pedraza et al

Correspondence to ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga and Liew—gender discrepancies at annual EULAR congresses: towards the gap narrowing by Monga et al

Response to: ‘Correspondence to ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga and Liew—gender discrepancies at annual EULAR congresses: towards the gap narrowing’ by Congiaraio et al

Case of postpartum axial spondyloarthritis

Response to: ‘Case of postpartum axial spondyloarthritis’ by Furushashi et al

Correspondence on ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Fallon et al

Response to: ‘Correspondence on ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Fallon et al’ by Fallon et al

Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care by Molina Collada et al

Response to: ‘Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care’ by Molina Collada et al

Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?

Response to: ‘Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?’ by Yamashita et al

Glucosamine and mortality: a note of caution

Response to: ‘Glucosamine and mortality: a note of caution’ by Conway

Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al

Response to: ‘Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al’ by Yuen et al

Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: “Correspondence to ‘Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study’ by Li et al”

Correction: Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation. 2-year results of the C-OPERA study, a phase III randomised trial

Terminology and definition of ‘antinuclear antibodies’: history and current debate

Correction: 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation. 2-year results of the C-OPERA study, a phase III randomised trial